Canady

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

Retrieved on: 
Tuesday, May 7, 2024
Research, Robotics, Oncology, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Risk, Innovation system, Doctor of Philosophy, SMC, RNS, Sheba Medical Center, Medicine, RMC, Oncology nursing, Purdue University, Canady, ROS, Surgical oncology, Entrepreneurship, Plasma, Johns Hopkins University, Patient, Multi, Argon, Safety, George Washington University, Microsoft Access, Cell death, Survival, IDE, University of Massachusetts, Treatment, Multimedia, Reactive nitrogen species, Engineer, CHCP, University, Apoptosis, FACS, Field line, Airline, Rush University Medical Center, Reactive oxygen species, Nursing

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

Key Points: 
  • US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
  • The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
  • The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
  • For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .

Groundbreaking Results Using Canady Helios™ Cold Plasma Treatment Published in MDPI Journal “Cancers”

Retrieved on: 
Wednesday, August 2, 2023
Research, Technology, Medical Devices, Surgery, Health Technology, Biotechnology, Robotics, Health, Science, Oncology, Canady, Cell death, RNS, Histone, Survival, Clinical trial, Immunotherapy, CHCP, Irreversible electroporation, Plasma, ROS, Cancer, LRR, Patient, Sheba Medical Center, Reactive oxygen species, Apoptosis, Education minister, Cell division, FACS, Neoplasm, Rush University Medical Center, Recurrence, FDA, Reactive nitrogen species, Messenger, Pharmaceutical industry

It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.

Key Points: 
  • It is estimated that 65% of solid tumor resections result in residual microscopic tumor cells at the surgical margin, which contributes to LRR and poor survival rates.
  • The recent trial reveals that treating the surgical margin following a tumorectomy significantly reduced local recurrence and increased overall survival.
  • CHCP opens a new and promising treatment for addressing the challenges of eradicating microscopic residual cancer cells following surgical tumor resection.
  • Jerome Canady, M.D., FACS, CEO stated, “We are very pleased to have our results published in the peer reviewed journal 'Cancers'.

USMI and JCRI Research Teams Develop Treatment System for COVID and other Respiratory Infections and Diseases

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Medical Devices, Infectious Diseases, Health, Oncology, Patent, Â, Cancer, Photon, Continuous positive airway pressure, Serial block-face scanning electron microscopy, Medical Innovation Bill, Laparoscopy, Ozone, CHCP, Caps, Canady, Ion, Abdomen, Wound healing, HERO, Patient, ROS, Skin, Ministry of Education (Malaysia), USPTO, Endoscopy, Virus, United States Patent and Trademark Office, Lung cancer, Method, CEO, THE, Reactive nitrogen species, LLC, RNS, Plasma medicine, COVID-19, FOR, Research, Plasma, Hydroxyl radical, Breast cancer, Singlet oxygen, Vaccine, Medical imaging

17/284,762) entitled SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERIC PLASMA.

Key Points: 
  • 17/284,762) entitled SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERIC PLASMA.
  • Jerome Canady, MD (CEO of USMI) stated, This is a very important addition to the companys patent portfolio.
  • JCRI-ABTS is also conducting research using the HERO system to deliver CAPs to treat cancer and other diseases to the abdomen and other body cavities via cannulas, laparoscopes, and endoscopes.
  • JCRI-ABTS is using Canady Helios Cold Plasma to research and develop new methods to selectively treat and eradicate cancer.

JCRI-ABTS and USMI Successfully Complete Phase 1 Multi-Center Clinical Trial Using Canady Helios™ Cold Plasma for the Treatment of Cancer

Retrieved on: 
Tuesday, April 20, 2021
Science, Biotechnology, Research, Surgery, Oncology, Health, Medical devices, Clinical trials, Spacecraft, Spaceflight, Medical physics, Radiobiology, Canady, Radiation therapy, Helios, Physical sciences, JCRI-ABTS, US Medical Innovations, JCRI-ABTS, US MEDICAL INNOVATIONS

b'The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios\xe2\x84\xa2 Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).

Key Points: 
  • b'The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios\xe2\x84\xa2 Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195).
  • This novel non-thermal process (24-27o C) has been developed for treating solid cancerous tumors.
  • Canady continued, \xe2\x80\x9cUnlike Chemo and Radiation Therapy, the Canady Helios\xe2\x84\xa2 Cold Plasma Therapy has many advantages.
  • It is highly selective because it only targets cancer cells without damaging surrounding healthy tissue.

JCRI-ABTS Seeks FDA Emergency Use Authorization for the Canady Helios Cold Plasma HERO System for the Treatment of COVID-19

Retrieved on: 
Wednesday, April 29, 2020
Health, FDA, Medical devices, Infectious diseases, Other Health, Clinical trials, Biotechnology, Physical sciences, Natural sciences, Physics, Astrophysics, Gases, Plasma, Canady, JCRI-ABTS, US Medical Innovations

Jerome Canady, M.D., CEO, explained, Plasma is an ionized gas often referred to as the '4th State of Matter.'"

Key Points: 
  • Jerome Canady, M.D., CEO, explained, Plasma is an ionized gas often referred to as the '4th State of Matter.'"
  • The Cold Plasma HERO system is a modified version of the FDA-approved Canady Plasma Smart Electrosurgical Generator XL-1000 (#K192124) and FDA-approved IDE (#G190165) Canady Helios Cold Plasma System for Solid Tumors CP-1000, specifically designed and patent pending for respiratory failure secondary to viruses, pneumonia and lung cancer.
  • The Canady HeliosTM Cold Plasma HEROTM System generates an ionized cold plasma which is blended with the Air/O2 from a ventilator or other oxygen source.
  • Dr. Canady continued, We see the Canady Helios Cold Plasma HERO System as a possible solution to the recovery of the COVID-19 infected virus patients.

Canady Helios Cold Plasma Scalpel Successfully Used by Chaim Sheba Medical Center Surgeons to Remove Inoperable Retroperitoneal Cancer

Retrieved on: 
Wednesday, January 29, 2020
Oncology, Medical devices, Health, Hospitals, Surgery, Biotechnology, Sheba Medical Center, Chaim Sheba, Tel HaShomer, Plasma medicine, Canady, Cities in Israel, Health, Israel

A surgical team at The Chaim Sheba Medical Center in Tel HaShomer, Israel, with coordination by US Medical Innovations, LLC (USMI), successfully used the Canady HeliosTM Cold Plasma Scalpel (CHCPS) for a rare advanced reoccurring inoperable retroperitoneal sarcoma.

Key Points: 
  • A surgical team at The Chaim Sheba Medical Center in Tel HaShomer, Israel, with coordination by US Medical Innovations, LLC (USMI), successfully used the Canady HeliosTM Cold Plasma Scalpel (CHCPS) for a rare advanced reoccurring inoperable retroperitoneal sarcoma.
  • CHCPS is new cold atmospheric plasma device that specifically eradicates microscopic remnants of cancer cells while sparing normal cells and tissue.
  • After a one-time pre-market Humanitarian Compassionate-Use Exemption from the Investigational Review Board at Sheba Medical Center, a surgical team successfully used the Canady HeliosTM Cold Plasma Scalpel (CHCPS) for the selective killing of cancerous tissue during the groundbreaking surgery.
  • Clinical trials will occur at Sheba Medical Center, Tel HaShomer, Israel and Rush University Medical Center, Chicago, Illinois starting February 2020.

US Medical Innovations Receives FDA 510(k) Clearance for the Canady Plasma Smart XL-1000 Generator

Retrieved on: 
Monday, November 25, 2019
Health, FDA, Medical devices, Surgery, Other Science, Science, Biotechnology, Physical sciences, Natural sciences, Physics, Dermatologic surgery, Electrosurgery, Surgery, Plasma, Canady

The unit provides various plasma modes including Canady Hybrid Plasma, Argon Plasma as well as standard cutting and coagulation modes.

Key Points: 
  • The unit provides various plasma modes including Canady Hybrid Plasma, Argon Plasma as well as standard cutting and coagulation modes.
  • View the full release here: https://www.businesswire.com/news/home/20191125005726/en/
    The Canady Plasma SMART XL-1000 Electrosurgical Generator is the first SMART electrosurgical generator in the world with its own operating system, the GRAPHICAL INTEGRATED MAGEMENT SURGICAL SYSTEM (GIMSS).
  • The Canady Plasma SMART XL-1000 Electrosurgical Generator was developed by Jerome Canady, M.D.
  • Dr. Canady (CEO, USMI and Chairman of USPIs family of companies) commented, The Canady Plasma SMART XL-1000 Electrosurgical Generator with Accessories is the next generation of Electrosurgical Generators.

Debra Canady from Round Rock, Texas Joined Reality TV Star Dr. Jennifer Arnold in Speaking at Ultimate Medical Academy's Spring Commencement

Retrieved on: 
Monday, April 23, 2018
The Little Couple, Johns Hopkins All Children's Hospital, Canady, Neonatology

She shared the stage with UMA's Commencement speaker, Dr. Jennifer Arnold, Medical Director of the Simulation Center at St. Petersburg, Florida's Johns Hopkins All Children's Hospital, neonatologist, and cancer survivor.

Key Points: 
  • She shared the stage with UMA's Commencement speaker, Dr. Jennifer Arnold, Medical Director of the Simulation Center at St. Petersburg, Florida's Johns Hopkins All Children's Hospital, neonatologist, and cancer survivor.
  • Arnold and Klein each have a rare form of dwarfism and have had multiple surgeries.
  • Canady, 56, is a recent graduate of the UMA Online Healthcare Management Associate Degree Program.
  • Ultimate Medical Academy students have access to academic advising, one-on-one or group tutoring, resume and interview coaching, job search assistance, technical support and more.